Pacira Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on June 13, 2017, by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.). The filing reports on corporate governance actions taken at the 2017 Annual Meeting of Stockholders held on June 13, 2017, and subsequent Board decisions on June 14, 2017.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten directors.
- New Appointment: Mark Froimson was appointed as a Class I director and assigned to the Science and Technology Committee. The Board determined he is independent under NASDAQ standards.
- Compensation: Mr. Froimson will receive the Company's standard compensation for non-employee directors.
Shareholder Voting Results and Governance
Stockholders approved three proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Three Class III directors were elected.
- Yvonne Greenstreet: 27,531,914 For; 3,301,479 Withheld.
- Gary Pace: 26,443,511 For; 4,389,882 Withheld.
- David Stack: 30,213,479 For; 619,914 Withheld.
- Proposal 2 (Auditor Ratification): KPMG LLP was ratified as the independent registered public accounting firm.
- For: 36,822,604; Against: 53,008; Abstain: 186,294.
- Proposal 3 (Executive Compensation): An advisory vote to approve named executive officer compensation was approved.
- For: 16,260,085; Against: 14,390,908; Abstain: 182,400.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed director, Mark Froimson, under NASDAQ listing standards.
- Note the significant split in the advisory vote on executive compensation (Proposal 3), where "Against" votes (14.4M) were nearly equal to "For" votes (16.3M).
- Confirm the standard compensation package for non-employee directors to assess the cost of the new board seat.
- Review the full proxy statement for details on the nominees and the specific compensation metrics approved in Proposal 3.